AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$PHIO

Phio Pharmaceuticals Corp.

Price · $PHIOvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $PHIO in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $PHIO in the last 30 days.

Top stories · $PHIOMore →
FEB 10·BenzingaHigh

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Phio Pharmaceuticals (NASDAQ: PHIO) shares surged after the company announced positive Phase 1b clinical trial results for its lead candidate, PH-762. The trial for skin cancer patients showed an 85% pathological response rate and complete tumor clearance in a significant number of patients at the highest dose. The company plans an FDA submission in Q2 2026 to discuss future clinical study design.

AUG 14·Motley Fool

Phio Posts Wider Loss in Fiscal Q2

Phio Pharmaceuticals ( NASDAQ:PHIO ) , a biotechnology company developing gene-silencing therapies for cancer, released its second quarter 2025 results on August 14, 2025. The quarter's key news included a GAAP EPS of $ ( 0.45 ) , missing the consensus GAAP estimate of $ ( 0.36 ) by $0.09.

News on $PHIO

All news →